RCM
NAVB

Rotella Capital Management’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Rotella Capital Management’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,120
Closed -$30K – 312
2015
Q4 		$30K Buy
+1,120
New +$38.9K 0.03% 382
2015
Q2 		– Sell
-642
Closed -$20K – 636
2015
Q1 		$20K Buy
+642
New +$21.7K 0.02% 492

Other funds holding NAVB

PM
Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Rotella Capital Management's NAVB Position: Q1 2016 in Review

Rotella Capital Management sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q1 2016, closing a stake of 1,120 shares — an estimated $30K sold.

Rotella Capital Management first reported a position in NAVB in Q1 2015 and held it in 2 quarters. The position peaked at $30K in Q4 2015. 74 funds tracked by Wall St. Rank hold NAVB as of Q1 2016.

  • Rotella Capital Management reported no remaining Navidea Biopharmaceuticals Inc. position as of Q1 2016 after selling out during the quarter.
  • Rotella Capital Management sold 1,120 Navidea Biopharmaceuticals Inc. shares in Q1 2016, an estimated $30K.
  • Rotella Capital Management first reported a position in Navidea Biopharmaceuticals Inc. in Q1 2015 and held it in 2 quarters.
  • Rotella Capital Management's Navidea Biopharmaceuticals Inc. position peaked at $30K in Q4 2015.
  • 74 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q1 2016.

Based on Rotella Capital Management's 13F filing for Q1 2016, filed 13 May 2016.